Literature DB >> 30562603

Correlation between antifungal resistance and virulence factors in Candida albicans recovered from vaginal specimens.

Houdaii H El-Houssaini1, Omnia M Elnabawy2, Hebatallah A Nasser1, Walid F Elkhatib3.   

Abstract

Candida albicans is considered as the leading species causing vulvovaginal candidiasis. Numerous virulence determinants and escalating resistance to antifungal therapy have contributed to its pathogenicity. However, correlation between resistance profiles and virulence patterns of C. albicans is not very well-investigated, which was the main focus of the current study. C. albicans isolates (n = 65) were recovered from vaginal swab specimens and identified to the species level. Antifungal susceptibilities of isolates were performed against (amphotericin B, nystatin, clotrimazole, fluconazole, voriconazole, and micafungin), and their minimum inhibitory concentrations (MICs) were determined according to Clinical and Laboratory Standards Institute (CLSI) guidelines. Virulence patterns including secreted hydrolases (phospholipase, aspartyl protease, and haemolysin), cell surface hydrophobicity, and biofilm production were evaluated. Associations between resistance profiles and virulence patterns of tested C. albicans isolates were analyzed. Isolates showed variable levels of resistance and virulence patterns. Furthermore, there are significant (p < 0.05) positive correlations between amphotericin B MICs and biofilm production. However, significant (p < 0.05) negative correlations are found between fluconazole and voriconazole MICs and cell surface hydrophobicity as well as biofilm production. Moreover, significant (p < 0.05) negative correlations are detected between voriconazole MICs and aspartyl protease production. This study revealed significant correlations between resistance profiles and virulence patterns of C. albicans isolates recovered from vulvovaginal specimens.
Copyright © 2018. Published by Elsevier Ltd.

Entities:  

Keywords:  Candida albicans; Correlations; Resistance; Virulence

Mesh:

Substances:

Year:  2018        PMID: 30562603     DOI: 10.1016/j.micpath.2018.12.028

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  5 in total

1.  Antibiofilm Activity of Essential Fatty Acids Against Candida albicans from Vulvovaginal Candidiasis and Bloodstream Infections.

Authors:  Shuai Wang; Peng Wang; Jun Liu; Chunxia Yang; Qiangyi Wang; Mingze Su; Ming Wei; Li Gu
Journal:  Infect Drug Resist       Date:  2022-08-03       Impact factor: 4.177

2.  Mechanisms of action of antimicrobial peptides ToAP2 and NDBP-5.7 against Candida albicans planktonic and biofilm cells.

Authors:  Jhones do Nascimento Dias; Calliandra de Souza Silva; Alyne Rodrigues de Araújo; Jessica Maria Teles Souza; Paulo Henrique de Holanda Veloso Júnior; Wanessa Felix Cabral; Maria da Glória da Silva; Peter Eaton; José Roberto de Souza de Almeida Leite; André Moraes Nicola; Patrícia Albuquerque; Ildinete Silva-Pereira
Journal:  Sci Rep       Date:  2020-06-25       Impact factor: 4.379

Review 3.  Pathogenesis and Clinical Relevance of Candida Biofilms in Vulvovaginal Candidiasis.

Authors:  Carmen Rodríguez-Cerdeira; Erick Martínez-Herrera; Miguel Carnero-Gregorio; Adriana López-Barcenas; Gabriella Fabbrocini; Monika Fida; May El-Samahy; José Luís González-Cespón
Journal:  Front Microbiol       Date:  2020-11-11       Impact factor: 5.640

4.  Candida albicans  Genotyping and Relationship of Virulence Factors with Fluconazole Tolerance in Infected Pediatric Patients.

Authors:  Ghada El-Saeed Mashaly; Mayada Sabry Zeid
Journal:  Infect Drug Resist       Date:  2022-04-21       Impact factor: 4.177

5.  Relationship between antifungal susceptibility profile and virulence factors in Candida albicans isolated from nail specimens.

Authors:  Faezeh Mohammadi; Zeinab Ghasemi; Behnaz Familsatarian; Eelham Salehi; Somayeh Sharifynia; Ameneh Barikani; Monirsadat Mirzadeh; Mohammad Ali Hosseini
Journal:  Rev Soc Bras Med Trop       Date:  2020-02-07       Impact factor: 1.581

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.